Annual report pursuant to Section 13 and 15(d)

Revenue - Narrative (Details)

v3.20.1
Revenue - Narrative (Details)
€ in Millions
 1 Months Ended 12 Months Ended
Feb. 08, 2018
USD ($)
swap_option
research_program
unit_of_accounting
license
May 02, 2017
USD ($)
unit_of_accounting
Feb. 27, 2017
USD ($)
Jan. 04, 2017
USD ($)
product
Jan. 04, 2017
EUR (€)
Jan. 04, 2017
USD ($)
product
Jan. 04, 2017
USD ($)
bispecific_therapeutic_program
product
Jan. 04, 2017
USD ($)
research_program
product
Jan. 04, 2017
USD ($)
extension_option
product
Jan. 04, 2017
USD ($)
unit_of_accounting
product
Jan. 04, 2017
USD ($)
product
license
Feb. 28, 2019
EUR (€)
Feb. 28, 2019
USD ($)
Dec. 31, 2018
EUR (€)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Disaggregation of Revenue [Line Items]                                  
Revenue capitalized   $ 1,100,000                              
Capitalized transaction cost, net                               $ 300,000  
Revenues                               46,279,000 $ 29,101,000
Additions to contract with customer, liability                               0  
Contract with customer, liability, revenue recognized                               32,200,000  
Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Remaining performance obligation                               24,700,000  
Revenues                               2,493,000 5,413,000
AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Remaining performance obligation                               26,000,000  
Capitalized contract cost, net   $ 1,600,000                              
Capitalized transaction cost, net                               700,000  
Capitalized contract cost, amortization                               400,000  
Research collaboration agreement term   5 years                              
Revenues                               25,828,000 17,632,000
Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Remaining performance obligation                               19,400,000  
Capitalized contract cost, net       $ 0   $ 0 $ 0 $ 0 $ 0 $ 0 $ 0            
Capitalized contract cost, amortization                               200,000  
Revenues                               15,048,000 4,508,000
Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term       3 years                          
ASKA Pharmaceutical Co. Ltd.                                  
Disaggregation of Revenue [Line Items]                                  
Capitalized contract cost, net     $ 300,000                            
Capitalized contract cost, amortization                               300,000  
Evaluation period     60 days                            
License and Collaboration Agreement | Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Period after effective date agreements may be terminated 12 months                                
Contract termination advance notice period 90 days                                
Agreement termination advance notice period if marketing approval obtained 180 days                                
Agreement termination notice period upon material breach by the Company 90 days                                
Contract termination due to material breach, additional notice period if the breach is not susceptible 90 days                                
Number of licenses | license 3                                
Number of swap options | swap_option 2                                
Number of performance obligations | unit_of_accounting 6                                
Number of research programs | research_program 3                                
License and Collaboration Agreement | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Period after effective date agreements may be terminated   12 months                              
Contract termination advance notice period   90 days                              
Agreement termination advance notice period if marketing approval obtained   180 days                              
Agreement termination notice period upon material breach by the Company   180 days                              
Agreement termination notice period upon breach of payment obligations by the Company   30 days                              
Contract termination due to material breach, additional notice period if the breach is not susceptible   180 days                              
Number of performance obligations | unit_of_accounting   16                              
License and Collaboration Agreement | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Number of licenses | license                     5            
Number of performance obligations | unit_of_accounting                   10              
Number of research programs             5 3                  
Sales Milestones | Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Current deferred revenue                               4,500,000  
Non-current deferred revenue                               16,000,000  
Sales Milestones | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Current deferred revenue                               1,000,000  
Non-current deferred revenue                               17,500,000  
Sales Milestones | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Deferred revenue                               5,700,000  
Non-current deferred revenue                               $ 13,700,000  
Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Period after effective date agreements may be terminated       12 months                          
Contract termination advance notice period       180 days                          
Revenues                       € 1.5 $ 1,700,000 € 0.5 $ 600,000    
Number of collaboration products | product       4   4 4 4 4 4 4            
Strategic Partnerships and Other License Agreements | ASKA Pharmaceutical Co. Ltd.                                  
Disaggregation of Revenue [Line Items]                                  
Revenues                                 $ 0
Upfront Payment | Seattle Genetics                                  
Disaggregation of Revenue [Line Items]                                  
Proceeds from advances for research and development services $ 30,000,000                                
Collaboration revenue (ASC 808) 4,900,000                                
Deferred revenue $ 1,200,000,000                                
Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   $ 45,000,000                              
Upfront Payment | ASKA Pharmaceutical Co. Ltd.                                  
Disaggregation of Revenue [Line Items]                                  
Upfront option payment received     $ 2,750,000                            
Upfront Payment | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Proceeds from advances for research and development services         € 30.0 $ 32,000,000                      
Additional Other Research Services | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   4,700,000                              
Estimated Development and Manufacturing Services | Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   14,200,000                              
Extension Term | Les Laboratoires Servier and Institut de Recherches Internationales Servier | Research and Development Services                                  
Disaggregation of Revenue [Line Items]                                  
Research collaboration agreement term       1 year                          
Number of agreement extension options | extension_option                 2                
Sales Milestones | Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   12,500,000                              
Estimated Phase 2a Services | Upfront Payment | AstraZeneca                                  
Disaggregation of Revenue [Line Items]                                  
Allocable arrangement consideration   $ 4,700,000                              
Minimum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Agreement termination notice period upon material breach by the Company       90 days                          
Maximum | Strategic Partnerships and Other License Agreements | Les Laboratoires Servier and Institut de Recherches Internationales Servier                                  
Disaggregation of Revenue [Line Items]                                  
Agreement termination notice period upon material breach by the Company       120 days